Clinical applications and availability of CD4+ T cell count testing in sub-Saharan Africa

Cytometry Part B - Clinical Cytometry

Volumn 74, Issue SUPPL. 1, 2008, Pages

  Taiwo, Babafemi O ^a,b   Murphy, Robert L ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

CD 4 count; Flow cytometry; Sub Saharan Africa

Indexed keywords

ANTIRETROVIRUS AGENT; COTRIMOXAZOLE; DIDANOSINE; FLUCONAZOLE; NEVIRAPINE; STEROID; TENOFOVIR;

AFRICA; ANTIBIOTIC PROPHYLAXIS; CD4 LYMPHOCYTE COUNT; DEVICE; DISEASE TRANSMISSION; FLOW CYTOMETRY; HOST SUSCEPTIBILITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; INFECTION; LIVER TOXICITY; MORTALITY; PATHOGENESIS; PHYSICAL EXAMINATION; PRIORITY JOURNAL; RASH; REVIEW; AFRICA SOUTH OF THE SAHARA; AIDS RELATED COMPLEX; IMMUNOLOGICAL MONITORING; IMMUNOLOGY; METHODOLOGY; PATHOLOGY;

AFRICA SOUTH OF THE SAHARA; AIDS-RELATED OPPORTUNISTIC INFECTIONS; CD4 LYMPHOCYTE COUNT; DISEASE TRANSMISSION, VERTICAL; HIV INFECTIONS; HUMANS; MONITORING, IMMUNOLOGIC;

EID: 42449125184     PISSN: 15524949     EISSN: 15524957     Source Type: Journal    
DOI: 10.1002/cyto.b.20383     Document Type: Review

References (74)

1. UNAIDS report on the global AIDS epidemic (May 2006). Available at http://www.unaids.org/en/HIV_data/2006GlobalReport/default.asp (accessed June 12, 2007).
2. Schnittman SM, Lane HC, Greenhouse J, Justement JS, Baseler M, Fauci AS. Preferential infection of CD4R memory T cells by human immunodeficiency virus type 1: Evidence for a role in the selective T-cell functional defects observed in infected individuals. Proc Natl Acad Sci USA 1990;87:6058-6062.
3. Veazey RS, Marx PA, Lackner AA. The mucosal immune system: Primary targets for HIV and AIDS. Trends Immunol 2001;22:626-633.
4. Veazey RS, DeMaria M, Chalifoux LV, Shvetz DE, Pauley DR, Knight HL, Rosenzweig M, Johnson RP, Desrosiers RC, Lackner AA. Gastrointestinal tract as a major site of CD4+ T cell depletion and viral replication in SIV infection. Science 1998;280:427-431.
5. + T cells in lymphoid tissues during simian immunodeficiency virus infection J Virol 2000;74:11001-11007.
6. Gottlieb GS, Sow PS, Hawes SE, Ndoye I, Redman M, Coll-Seck AM, Faye-Niang MA, Diop A, Kuypers JM, Critchlow CW, Respess R, Mullins JI, Kiviat NB. Equal plasma viral loads predict a similar rate of CD4+ T cell decline in human immunodeficiency virus (HIV) type 1- and HIV-2-infected individuals from Senegal, West Africa. J Infect Dis 2002;185:905-914.
7. Rosenberg ES, Billingsley JM, Caliendo AM, Boswell SL, Sax PE, Kalams SA, Walker BD. Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia. Science 1997;278:1447-1450.
8. Egger M, May M, Chene G, Phillips AN, Ledergerber B, Dabis F, Costagliola D, D'Arminio Monforte A, de Wolf F, Reiss P, Lundgren JD, Justice AC, Staszewski S, Leport C, Hogg RS, Sabin CA, Gill MJ, Salzberger B, Sterne JA; ART Cohort Collaboration. Prognosis of HIV-1 infected drug patients starting highly active antiretroviral therapy: A collaborative analysis of prospective studies. Lancet 2002;360:119-129.
9. + lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 1997;126:946-954.
10. 9 cells/L. Ann Intern Med 2003;139:810-816.
11. Lange CG, Lederman MM, Medvik K, Asaad R, Wild M, Kalayjian R, Valdez H. Nadir CD4+ T cell count and numbers of CD28+ CD4+ T cells predict functional responses to immunizations in chronic HIV-1 infection. AIDS 2003;17:2015-2023.
12. Sterling TR, Chaisson RE, Keruly J, Moore RD. Improved outcomes with earlier initiation of highly active antiretroviral therapy among human immunodeficiency virus - Infected patients who achieve durable virologic suppression: Longer follow-up of an observational cohort study. J Infect Dis 2003;188:1659-1665.
13. World Health Organisation. ARV treatment guidelines and technical and operational recommendations for ART (2006). Available at http://www.who.int/hiv/ pub/guidelines/artadultguidelines.pdf (accessed August 17, 2007).
14. WHO Clinical Charts and Tables. Available at http://www.womenchildrenhiv. org/wchiv?page=charts-00-00 (accessed August 22, 2007).
15. Narita M, Ashkin D, Hollender ES, Pitchenick AE. Paradoxical worsening of tuberculosis following antiretroviral therapy in patients with AIDS. Am J Respir Crit Care Med 1998;158:157-161.
16. Phillips AN, Sabin CA, Mocroft A, Janossy G. HIV results in the frame: Antiviral therapy [letter]. Nature 1995;375:195.
17. Pakker NG, Notermans DW, de Boer RJ, Roos MT, de Wolf F, Hill A, Leonard JM, Danner SA, Miedema F, Schellekens PT. Biphasic kinetics of peripheral blood T cells after triple combination therapy in HIV-1 infection: A composite of redistribution and proliferation. Nat Med 1998;4:208-214.
18. Riddler SA, Haubrich R, DiRienzo G, Peeples L, Powderly WG for the AIDS Clinical Trials Group 5142 Study Team. A prospective, randomized, phase III trial of NRTI-, PI-, and NNRTI-sparing regimens for initial treatment of HIV infection. In: ACTG 5142. XVI International AIDS Conference, Toronto. August 13-18, 2006. Abstract THLB0204.
19. Smith CJ, Sabin CA, Youle MS, Kinloch-de Loes S, Lampe FC, Madge S, Cropley I, Johnson MA, Phillips AN. Factors influencing increases in CD4 cell counts of HIV-positive persons receiving long-term highly active antiretroviral therapy. J Infect Dis 2004;190:1860-1868.
20. Koletar SL, Heald AE, Finkelstein D, Hafner R, Currier JS, McCutchan JA, Vallee M, Torriani FJ, Powderly WG, Fass RJ, Murphy RL;ACTG 888 Study Team. A prospective study of discontinuing primary and secondary Pneumocystis carinii pneumonia prophylaxis after CD4 cell count increase to >200 X 106/l. AIDS 2001;15:1509-1515.
21. Vibhagool A, Sungkanuparph S, Mootsikapun P, Chetchotisakd P, Tansuphaswaswadikul S, Bowonwatanuwong C, Ingsathit A. Discontinuation of secondary prophylaxis for cryptococcal meningitis in human immunodeficiency virus-infected patients treated with highly active antiretroviral therapy: A prospective, multicenter, randomized study. Clin Infect Dis 2003;36:1329-1331.
22. Clooney EL. Clinical indicators of immune restoration following highly active antiretroviral therapy. Clin Infect Dis 2002;34:224-233.
23. Shelburne SA, Visnegarwala F, Darcourt J, Graviss EA, Giordano TP, White AC Jr, Hamill RJ. Incidence and risk factors for immune reconstitution inflammatory syndrome during highly active antiretroviral therapy. AIDS 2005;19:399-406.
24. Dieterich DT, Robinson PA, Love J, Stern JO. Drug-induced liver injury associated with the use of nonnucleoside reverse-transcriptase inhibitors. Clin Infect Dis 2004;38 (Suppl 2):S80-S89.
25. WHO. Antiretroviral drugs for treating pregnant women and preventing HIV infection in infants: Towards universal access. Recommendations for a public health approach. Available at http://www.who.int/mv/pub/guidelines/ pmtctguidelines3.pdf (accessed September 17, 2007).
26. Strategies for Management of Antiretroviral Therapy (SMART) Study Group, El-Sadr WM, Lundgren JD, Neaton JD, Gordin F, Abrams D, Arduino RC, Babiker A, Burman W, Clumeck N, Cohen CJ, Cohn D, Cooper D, Darbyshire J, Emery S, Fätkenheuer G, Gazzard B, Grund B, Hoy J, Klingman K, Losso M, Markowitz N, Neuhaus J, Phillips A, Rappoport C. CD4+count-guided interruption of antiretroviral treatment. N Eng J Med 2006;355:2283-2296.
27. Danel C, Moh R, Minga A, Anzian A, Ba-Gomis O, Kanga C, Nzunetu G, Gabillard D, Rouet F, Sorho S, Chaix ML, Eholié S, Menan H, Sauvageot D, Bissagnene E, Salamon R, Anglaret X; Trivacan ANRS 1269 trial group. CD4-guided structured antiretroviral treatment interruption strategy in HIV-infected adults in West Africa (Trivacan ANRS 1269 trial): A randomised trial. Lancet 2006;367:1981-1989.
28. Badri M, Lawn SD, Woods R. Short-term risk of AIDS or death in people infected with HIV-1 before antiretroviral therapy in South Africa. A longitudinal study. Lancet 2006;368:1254-1259.
29. Feki S, Rekaya Z, Ben Chaaben T, Zribi A, Boukef K, Jenhani F. Determination of T-lymphocyte subsets in a North African population (Tunisia): Establishment of normal ranges and results in HIV-infected individuals. Dis Markers 1998;14:161-164.
30. Tugume SB, Piwowar EM, Lutalo T, Mugyenyi PN, Grant RM, Mangeni FW, Pattishall K, Katongole-Mbidde E. Hematological reference ranges among healthy Ugandans. Clin Diagn Lab Immunol 1995;2:233-235.
31. Menard D, Mandeng MJ, Tothy MB, Kelembho EK, Gresenguet G, Takarmin A. Immunohematological reference ranges for adults from the Central African Republic. Clin Diagn Lab Immunol 2003;10:443-445.
32. Zekeng L, Sadjo A, Meli J, Kaptue L, Mpoudi Ngole E, Hess G, Babiel R. T lymphocyte subset values among healthy Camerounians. J Acquir Immne Defic Syndr Hum Retrovirol 1997;14:82-83.
33. Bussmann H, Wester CW, Masupu KV, Peter T, Gaolekwe SM, Kim S, Reich AM, Ahn S, Wu Y, Thior I, Essex M, Marlink R. Low CD4 lymphocyte values in human immunodeficiency virus negative adults in Botswana. Clin Diagn Lab Immunol 2004;11:930-935.
34. Tsegaye A, Messele T, Tilahun T, Hailu E, Sahlu T, Doorly R, Fontanet AL, Rinke de Wit TF. Immunohematological reference ranges for adult Ethiopians. Clin Diagn Lab Immunol 1999;6:410-414.
35. Malone JL, Simms TE, Gray GC, Wagner KF, Burge JR, Burke DS. Sources of variability in repeated T-helper lymphocyte counts from human immunodeficiency virus type 1 infected patients: Total lymphocyte count fluctuation and diurnal cycle are important. J Acquir Immune Defic Syndr 1990;3:144-151.
36. Morris L, Martin DJ, Bredell H, Nyoka SN, Sacks L, Pendle S, Page-Shipp L, Karp CL, Sterling TR, Quinn TC, Chaisson RE. Human immuno-denciency virus-1 RNA levels and CD4 lymphocyte counts during treatment for active tuberculosis, in South African patients. J Infect Dis 2003;187:1967-1971.
37. Fairley CK, Spelman D, Street A, Jennens ID, Spicer WJ, Crowe S. CD4 lymphocyte numbers after splenectomy in patients infected with the human immunodeficiency virus. Int J STD AIDS 1994;5:177-181.
38. Van Geertruyden JP, Mulenga M, Kasongo W, Polman K, Colebunders R, Kestens L, D'Alessandro U. CD4 T-cell count and HIV-1 infection in adults with uncomplicated malaria. J Acquir Immune Defic Syndr 2006;43:363-367.
39. Harrison LH, Schechter M. Coinfection with HTLV-1 and HIV: Increase in HTLV-I-related outcomes but not accelerated HIV disease progression? AIDS Patient Care STDS 1998;12:619-623.
40. Schleicher GK, Hopley MJ, Feldman C. CD4 T-lymphocyte subset counts in HIV-seropositive patients during the course of community-acquired pneumonia caused by Streptococcus pneumoniae. Clin Microbiol Infect 2004;10:587-589.
41. Glück T, Kiefmann B, Grohmann M, Falk W, Straub RH, Schölmerich J. Immune status and risk for infection in patients receiving chronic immunosuppressive therapy. J Rheumatol 2005;32:1473-1480.
42. + T-lymphopenia without HIV infection. An investigation of cases in the United States. N Engl J Med 1993;328:373-379.
43. Hanamura I, Wakita A, Harada S, Tsuboi K, Komatsu H, Banno S, Iwaki O, Takeuchi G, Nitta M, Ueda R. Idiopathic CD4+ T-lymphocytopenia in a non-Hodgkin's lymphoma patient. Intern Med 1997;36:643-646.
44. Girinsky T, Baume D, Socié G, Pico JL, Malaise E, Cosset JM. Blood cell kinetics after a 385 cGy total body irradiation given to a CML patient for bone marrow transplantation. Bone Marrow Transplant 1991;7:317-320.
45. Kaiser FE, Morley JE. Idiopathic CD4+ T lymphopenia in older persons. J Am Geriatr Soc 1994;42:1291-1294.
46. Barrios A, Rendón A, Negredo E, Barreiro P, Garcia-Benayas T, Labarga P, Santos J, Domingo P, Sánchez-Conde M, Maida I, Martin-Carbonero L, Núñez M, Blanco F, Clotet B, Sambeat MA, Gil P, Gonzalez-Lahoz J, Cooper D, Soriano V Paradoxical CD4+ T cell decline in HIV-infected patients with complete virus suppression taking tenofovir and didanosine. AIDS 2005;19:569-575.
47. Bisson GP, Gross R, Strom JB, Rollins C, Bellamy S, Weinstein R, Friedman H, Dickinson D, Frank I, Strom BL, Gaolathe T, Ndwapi N. Diagnostic accuracy of CD4 cell count increase for virologic response after initiating highly active antiretroviral therapy. AIDS 2006;20:1613-1619.
48. Novitsky V, Wester CW, DeGruttola V, Bussmann H, Gaseitsiwe S, Thomas A, Moyo S, Musonda R, Van Widenfelt E, Marlink RG, Essex M. The 67N 70R 215Y TAM pathway in HIV-1 subtype C infection treated with ZDV/ddI-containing ART in Southern Africa. Conference on retroviruses and opportunistic infections 2007. AIDS Res Hum Retroviruses 2007;23:868-878.
49. Sungkanuparph S, Manosuthi W, Kiertiburanakul S, Piyavong B, Chumpathat N, Chantratita W. Options for a second-line antiretroviral regimen for HIV type 1-infected patients whose initial regimen of a fixed-dose combination of stavudine, lamivudine, and nevirapine fails. Clin Infect Dis 2007;44:447-452.
50. Spacek LA, Shihab HM, Lutwama F, Summerton J, Mayanja H, Kamya M, Ronald A, Margolick JB, Nilles TL, Quinn TC. Evaluation of a low-cost method, the Guava EasyCD4 assay, to enumerate CD4 positive lymphocytes count in HIV-infected patients in the United States and Uganda. J Acquir Immun Defic Syndr 2006;41:607-610.
51. + T lymphocytes in resource-limited settings: The ANRS 12-26 study. AIDS 2003;17:2201-2208.
52. Crowe S, Turnbull S, Oelrichs R, Dunne A. Monitoring of human immunodeficiency virus infection in resource-constrained countries. Clin Infect Dis 2003;37 (Suppl 1):S25-S35.
53. Balakrishnan P, Dunne M, Kumarasamy N, Crowe S, Subbulakshmi G, Ganesh AK, Cecelia AJ, Roth P, Mayer KH, Thyagarajan SP, Solomon S. An inexpensive, simple and manual method of CD4 T-cell quantitation in HIV-infected individuals for use in developing countries. J Acquir Immune Defic Syndr 2004;36:1006-1010.
54. + T-lymphocyte enumeration for implementation in developing countries. J Acquir Immune Defic Syndr 2001;26:193-195.
55. + lymphocyte counts determined by enzyme immunoassay (TRAx CD4 test kit) and flow cytometry. Clin Diagn Lab Immunol 1996;3:371-373.
56. Cassens U, Göhde W, Ruling G, Gröning A, Schlenke R Lehman LG, Traoré Y, Servais J, Henin Y, Reichelt D, Greve B. Simplified volumetric flow cytometry allows feasible and accurate determination of CD4 T lymphocytes in immunodeficient patients worldwide. Antivir Ther 2004;9:395-405.
57. Imade GE, Badung B, Pam S, Agbaji O, Egah D, Sagay AS, Sankalé JL, Kapiga S, Idoko J, Kanki P. Comparison of a new, affordable flow cytometric method and the manual magnetic bead technique for CD4 T-lymphocyte counting in a northern Nigerian setting. Clin Diagn Lab Immunol 2005;12:224-227.
58. Dieye TN, Vereecken C, Diallo AA, Ondoa P, Diaw PA, Camara M, Karam F, Mboup S, Kestens L. Absolute CD4 T-cell counting in resource-poor settings: Direct volumetric measurements versus bead-based clinical flow cytometry instruments. J Acquir Immune Defic Syndr 2005;39:32-37.
59. Pattanapanyasat K, Lerdwana S, Noulsri E, Chaowanachan T, Wasinrapee P, Sakulploy N, Pobkeeree V, Suksripanich O, Thanprasertsuk S, Spira TJ, Tappero JW, Levine WC. Evaluation of a new single-parameter volumetric flow cytometer (CyFlow(green)) for enumeration of absolute CD4+ T lymphocytes in human immunodeficiency virus type 1-infected Thai patients. Clin Diagn Lab Immunol 2005;12:1416-1424.
60. Karcher H, Bohning D, Downing R, Mashate S, Harms G. Comparison of two alternative methods for CD4+ T cell determination (Coulter manual CD4 count and CyFlow) against standard dual platform flow cytometry in Uganda. Cytometry B Clin Cytometry 2006;70B:163-169.
61. Fryland M, Chaillet P, Zachariah R, Barnaba A, Bonte L, Andereassen R, Charrondière S, Teck R, Didakus O. The Partec CyFlow counter could provide an option for CD4+ T cell monitoring in the context of scaling-up antiretroviral treatment at the district level in Malawi. Trans R Soc Trop Med Hyg 2006;100:980-985.
62. Zijenah LS, Kadzirange G, Madzime S, Borok M, Mudiwa C, Tobaiwa O, Mucheche M, Rusakaniko S, Katzenstein DA. Affordable flow cytometry for enumeration of absolute CD4+ T-lymphocytes to identify subtype C HIV-1 infected adults requiring antiretroviral therapy (ART) and monitoring response to ART in a resource-limited setting. J Transl Med 2006;4:33.
63. Lynen L, Teav S, Vereecken C, De Munter P, An S, Jacques G, Kestens L. Validation of primary CD4 gating as an affordable strategy for absolute CD4 counting in Cambodia. J Acquir Immune Defic Syndr 2006;43:179-185.
64. Manasa J, Musabaike H, Masimirembwa C, Burke E, Luthy R, Mudzori J. Evaluation of the Partec flow cytometer against the BD FACS-Calibur system for monitoring immune responses of human immunodeficiency virus-infected patients in Zimbabwe. Clin Vaccine Immunol 2007;14:293-298.
65. Ceffa S, Erba F, Assane M, Coelho E, Calgaro M, Brando B. Panleucogating as an accurate and affordable flow cytometric protocol to analyse lymphocyte subsets among HIV-positive patients on HAART treatment in Mozambique. J Biol Regul Homeost Agents 2005;19:169-175.
66. Carella AV, Moss MW, Provost V, Quinn TC. A manual bead assay for the determination of absolute CD4+ and CD8+ lymphocyte counts in human immunodeficiency virus-infected individuals. Clin Diagn Lab Immunol 1995;2:623-625.
67. Gernow A, Lisse IM, Bottiger B, Christensen L, Brattegaard K. Determination of CD4+ and CD8+ lymphocytes with the cytosphere assay: A comparative study with flow cytometry and the immunoalkaline phosphatase method. Clin Immunol Immunopathol 1995;76:135-141.
68. Landay A, Ho JL, Horn D, Russell T, Zwerner R, Minuty JG, Kataaha P, Mmiro F, Jackson B. A rapid manual method for CD4+ T cell quantitation for use in developing countries. AIDS 1993;7:1565-1568.
69. Post FA, Wood R, Maartens G. CD4 and total lymphocyte counts as predictors of HIV disease progression. QJM 1996;89:505-508.
70. Akinola NO, Olasode O, Adediran IA, Onayemi O, Murainah A, Irinoye O, Elujoba AA, Durosinmi MA. The search for a predictor of CD4 cell count continues: Total lymphocyte count is not a substitute for CD4 cell count in the management of HIV-infected individuals in a resource-limited setting. Clin Infect Dis 2004;39:579-581.
71. Akanbi M, Taiwo B, Welty L, Idoko J, Samson I, Gwamzhi N, Murphy R. Sensitivity of total lymphocyte count as a predictor of CD4 count in ARV naive HIV patient at JUTH, Jos, Nigeria. In: XVI International AIDS Conference, Toronto, 2006. Abstract MOPE0151.
72. Spacek LA, Griswold M, Quinn TC, Moore RD. Total lymphocyte and hemoglobin combined in algorithm to initiate the use of highly active antiretroviral therapy in resource-limited settings. AIDS 2003;17:1311-1317.
73. Chen RY, Westfall AO, Hardin JM, Miller-Hardwick C, Stringer JS, Raper JL, Vermund SH, Gotuzzo E, Allison J, Saag MS. Complete blood cell count as a surrogate CD4 cell marker for HIV monitoring in resource-limited settings. J Acquir Immune Defic Syndr 2007;44:525-530.
74. Ledergerber B, Mocroft A, Reiss P, Furrer H, Kirk O, Bickel M, Uberti-Foppa C, Pradier C, D'Arminio Monforte A, Schneider MM, Lundgren JD; Eight European Study Groups. Discontinuation of secondary prophylaxis against Pneumocystis carinii pneumonia in patients with HIV infection who have a response to antiretroviral therapy. N Engl J Med 2001;344:168-174.